source
- Revolution Medicines' Daraxonrasib Doubles Survival in Pancreatic Cancer Trial, Study ShowsResults from a late-stage trial of the experimental pill daraxonrasib were presented at the American Society of Clinical Oncology meeting. The data showed that patients receiving the drug lived alm…
- Ivonescimab cuts death risk by 34% in Chinese trial for squamous NSCLCData presented at the American Society of Clinical Oncology showed that ivonescimab, a bispecific antibody combining two established cancer drugs, lowered the risk of death by 34% compared with sta…